Eli Lilly production plant said to be under renewed FDA scrutiny

admin

Eli Lilly production plant said to be under renewed FDA scrutiny


Grandbrothers/iStock Editorial via Getty Images

The U.S. Food and Drug Administration (FDA) has found new manufacturing lapses at Eli Lilly’s (NYSE:LLY) Branchburg, New Jersey, plant, which has already been under regulatory scrutiny, Reuters reported Friday, citing government records.

The findings include insufficient controls on electronic records detailing

SOURCE

Leave a Comment